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Abstract
We examined the molecular pharmacology and in vivo effects of a TRPV1 receptor antagonist, N-
(4-Tertiarybutylphenyl)-4(3-cholorphyridin-2-yl)-tetrahydro-pyrazine1(2H) – carboxamide
(BCTC) on the guinea pig TRPV1 cation channel. BCTC antagonized capsaicin-induced activation
and PMA-mediated activation of guinea pig TRPV1 with IC50 values of 12.2 ± 5.2 nM, and 0.85 ±
0.10 nM, respectively. In addition, BCTC (100 nM) completely blocked the ability of heterologously
expressed gpTRPV1 to respond to decreases in pH. Thus, BCTC is able to block polymodal
activation of gpTRPV1. Furthermore, in nodose ganglia cells, capsaicin induced Ca2+ influx through
TRPV1 channel was inhibited via BCTC in a concentration dependent manner. In in vivo studies
capsaicin (10 – 300 μM) delivered by aerosol to the pulmonary system of non-sensitized guinea pigs
produced an increase in cough frequency. In these studies, the tussigenic effects of capsaicin (300
μM) were blocked in a dose dependent fashion when BCTC (0.01–3.0 mg/kg, i.p.) was administered
30 minutes before challenge. The high dose of BCTC (3.0 mg/kg, i.p) produced a maximum
inhibition of capsaicin-induced cough of 65%. We also studied the effects of BCTC (0.03 and 3.0)
when administered 60 minutes before capsaicin. Under these conditions, BCTC (3.0 mg/kg, i.p)
produced a maximum decrease in capsaicin-induced cough of 31%. In ovalbumin passively sensitized
guinea pigs, we found that BCTC (1 and 3 mg/kg, i.p.) attenuated antigen ovalbumin (0.3%) cough
responses by 27% and 60%, respectively. We conclude that TRPV1 channel activation may play role
in cough mediated by antigen in sensitized guinea pigs. Our results supports increasing evidence
that TRPV1 may play a role in the generation of the cough response.
Background
The vanilloid receptor (TRPV1) is a member of a distinct
subgroup of transient receptor potential (TRP) family of
ion channels [1]. The neuronally expressed TRPV1 is a
non-selective, Ca2+ preferring, cation channel. The TRPV1
channel is activated by a number of different stimuli
including heat, acid certain arachidonic acid derivatives
and direct phosphorylation via PKC [2-5]. Moreover,
there is also evidence that various inflammatory media-
tors such as ATP, bradykinin, NGF or PGE2 may indirectly
lead to the activation of the TRPV1 channel via activation
of their respective receptors [6-9]. Current data suggests
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that receptor activation may lead to TRPV1 gating by
either generation of arachidonate via BK2 or through the
activation of PKC by P2Y1 [6-10]. These findings suggest
that TRPV1 may have a central role in inflammatory noci-
ception.
Within recent years, pulmonary researchers have shown
an interest in TRPV1 and the possible role of this receptor
in respiratory diseases [11]. TRPV1 has been linked to
playing significant role in the genesis of cough. Indeed,
cough is arguably the most common symptom associated
with pulmonary diseases, such as asthma, COPD and the
common cold [12-14]. The evidence for this linkage
between TRPV1 and cough is supported by several obser-
vations. (1) TRPV1 receptors are found on sensory airway
nerves that are important in the cough reflex [15-17]. (2)
Isolated pulmonary vagal afferent nerves are responsive to
TRPV1 stimulation and (3) TRPV1 agonists, such as capsa-
icin, elicit cough in animals and man [18-21]. (4) Further-
more, sensitivity of capsaicin-induced cough responses
following upper respiratory tract infection and in airway
inflammatory diseases such as asthma and COPD, are
increased relative to control responses [22,23]. Nonethe-
less, it is important to point out that although cough can
be provoked by aerosolized capsaicin to the airways, the
significance of TRPV1 receptors in cough associated with
pulmonary diseases remains to be fully elucidated.
N-(4-Tertiarybutylphenyl)-4(3-cholorphyridin-2-yl)tet-
rahydropyrazine-1(2H)-carbox-amide (BCTC) is a highly
potent and selective TRPV1 antagonist [24]. This new
pharmacological tool has been used to block TRPV1
responses in inflammatory and neuropathic pain models
[25]. Presently we studied the TRPV1 antagonist activity of
BCTC in HEK293OFF cells stably-expressing gpTRPV1 and
in isolated guinea pig nodose ganglia. As our primary
goal, we sought to utilize BCTC to examine the role of
TRPV1 receptors in antigen-induced cough in ovalbumin
sensitized guinea pigs. We found that BCTC attenuated
cough in a model of antigen-provoked cough.
Materials and methods
Animal care and use
These studies were performed in accordance to the NIH
GUIDE TO THE CARE AND USE OF LABORATORY ANI-
MALS and the Animal Welfare Act in an AAALAC-accred-
ited program.
RNA isolation, cloning and expression of guinea pig TRPV1
Male Hartley Short Hair guinea pigs (350 – 400 g) were
euthanized with CO2, and the nodose ganglia were dis-
sected and flash-frozen in liquid nitrogen prior to total
RNA isolation. Total RNA was prepared from nodose gan-
glia using the Ambion Totally RNA kit (Ambion, Austin,
TX, USA) according to the manufacturer's instructions.
First strand cDNA synthesis was carried out and used to
carry out PCR reactions using an Ex Taq Kit (Pan Vera,
Madison, WI, U.S.A.). Multiple primers were designed
based upon the published guinea pig sequence (GenBank
#AJ492922) and used to generate short fragments for
establishment of a consensus sequence. The resulting full
length sequence (GenBank #AY729017) was used to
clone a full length gpTRPV1 sequence from primary tissue.
The following primers were used to clone out gpTRPV1 in
two fragments P1:atgaagaaacgggctagtgtgg, P2: gcca-
gagccagtggtgtgaaccccttc, P3:gaaggggttcacaccactggctctggc,
P4: tcacttctcccctggaactgtcggactc. The resulting fragments
were used to create a full length gpTRPV1 cDNA sequence
which was subcloned between the NotI and EcoRV sites of
the pTRE2hyg vector (BD Biosciences, Clontech, Palo
Alto, CA) for sequence confirmation and Tet-promoter
controlled expression of gpTRPV1. Stably-transfected
HEK293TetOFF cells expressing gpTRPV1 under control of
the Tet-promoter were maintained in MEM medium (sup-
plemented with 10% Tet System Approved FBS/penicil-
lin/streptomycin/L-glutamine/geneticin G418, all from
Invitrogen, Caisbad, CA) at 37°C and 5% CO2  in a
humidified atmosphere.
Molecular pharmacology
Analysis of gpTRPV1 activity was carried out using FLIPR
as described previously [26]. Briefly, HEK293OFF cells sta-
bly-expressing gpTRPV1 were plated in black clear-bot-
tomed 96-well poly-lysine plates (BD Biosciences) at a
concentration of 40,000 cells per well in 200 μl of media
in the absence of doxycycline to allow for expression. The
plates were incubated for two days at 37°C and 5% CO2
to allow for optimal expression of TRPV1. The cells were
incubated in a buffer consisting of Hank's Balanced Salt
Solution (HBSS) containing 10 mM HEPES pH 7.4, BSA
1%, and probenecid 2.5 mM with the addition of the cal-
cium sensitive fluorescent dye Fluo-4AM (Molecular
Probes, Eugene, OR) (4 μM) for 1 hour at 37°C. The cells
were washed 3 times with the above buffer, which had
been heated to 37°C. A total of 100 μl of buffer was
placed in to each well and the plates were put in a 37°C
incubator for an additional 30 minutes prior to assay. All
compounds used in these studies were dissolved in dime-
thyl sulfoxide (DMSO) and vehicle alone (DMSO) was
used as a control. The cells were then placed in a FLIPR
(Molecular Devices, Sunnyvale CA) with a heated stage
maintained at 37°C for monitoring changes in fluores-
cent signal upon addition of agonist. After addition of
compound, change in fluorescence was monitored for a
period of 5 min and maximal increase in fluorescent sig-
nal was noted. Antagonist was added to cells in a volume
of 50 μl via the FLIPR and allowed to incubate for 6 min-
utes prior to addition of agonist. The change in fluores-
cence (max – min) upon addition of agonist was used to
assess activation.Cough 2006, 2:10 http://www.coughjournal.com/content/2/1/10
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Intracellular Ca2+ concentration measurements in nodose 
ganglia cells
Male Hartley guinea pigs (600 – 700 g, Charles River,
Bloomington, MA, USA) were euthanized with CO2. The
nodose ganglia were removed under aseptic conditions
and enzyme digested as previously described [17]. Briefly,
the isolated ganglia were washed in Hank's buffer (Gibco,
NY, USA) and then transferred to Hank's buffer contain-
ing collagenase (type IA, 1 mg ￿ ml-1) for 45 min at 37°C
in a water bath. The enzyme solution was aspirated from
the tissues, after which they were rinsed with Hank's
buffer and then incubated in Hank's buffer containing
DNAse IV (0.1 mg ￿ ml-1) for 15 min at 37°C in a water
bath. Tissues were washed with Hank's buffer and sub-
jected to gentle trituration using a Pasteur pipette. The
resulting cell suspension was filtered through a sterile
nylon mesh (Becton Dickinson Labware MA, USA) and
plated into poly-lysine coated petri dishes (Becton Dickin-
son Labware MA, USA). Cells were incubated for 3 hrs at
37°C prior to the intracellular Ca2+ measurements. Intra-
cellular Ca2+ concentrations in single nodose ganglia cells
was measured in Hank's buffer using Attofluor digital
ratiovision system (Atto Instrument, Maryland, USA).
Briefly, cells were incubated with Fura-2 acetoxy methyles-
tor (5 μg ml-1, Molecular Probes), a calcium sensitive flu-
orescence dye, in HBSS containing 0.4% bovine serum
albumin (BSA) for 45 min at 37°C. The dye-loading solu-
tion was removed and the cells were washed three times
with HBSS containing 0.4% BSA. Fluorescence in single
cells was measured at a single emission wavelength (510
nm) with double excitatory wavelength (334 and 380
nm), using Attofluor digital ratiovision system. Intracellu-
lar Ca2+ concentration was estimated by ratio of fluores-
cence at excitation wavelengths of 334 and 380 nm.
Capsaicin responses were elicited by direct additions to
the cell culture buffer during real-time recording
Capsaicin-induced cough
All cough experiments were performed in conscious
guinea pigs (Male Hartley, 400 – 500 g, Charles River,
Bloomington, MA, USA) using methods described by
Bolser et al., [20]. In the first experiment, the effect of
graded concentrations of aerosolized capsaicin was exam-
ined on cough frequency. Overnight fasted guinea pigs
were placed in a 12 × 14-inch chamber and exposed to
aerosolized capsaicin (10 – 300 μM, for 4 min) produced
by a Ultra-NeB 99 Devilbiss nebulizer (Somerset, PA) to
elicit cough. Experiments were conducted in a parallel
design where each animal was exposed only once to cap-
saicin. The number of coughs were detected by a micro-
phone placed in the chamber and verified by a trained
observer. The signal from the microphone was relayed to
a polygraph that provided a record of the number of
coughs. The antitussive activity of BCTC was determined
against cough provoked by capsaicin (300 μM). In these
studies, BCTC (0.01 – 10 mg/kg, i.p.) was given 30 min-
utes before capsaicin challenge. In a separate study, the
cough suppressant effects of BCTC (0.03 and 3.0 mg/kg,
i.p.) was studied at 1 hour after i.p. administration.
Antigen-induced cough
Male Hartley guinea pigs (300 – 350 g, Charles River,
Bloomington, MA, USA) were actively sensitized to oval-
bumin over a 27 day regimen. On day 1, animals were
administered ovalbumin (100 μg, i.p.) and aluminum
hydroxide (200 mg, i.p.) suspended in 0.5 ml of water.
On day 7, animals were administered an additional dose
of ovalbumin (100 μg, i.p.). The animals were used 27
days after the initial ovalbumin dose when they weighed
between 450 – 500 g. Allergic cough studies were per-
formed in an exposure chamber similar to the one used to
examine capsaicin-evoked cough responses. The concen-
tration of ovalbumin (0.3%) used to elicit cough was
selected based on studies by Bolser et al., [20]. BCTC (1
and 3 mg/kg, i.p.) was given 30 minutes before ovalbu-
min (0.3%). The activity of a second TRPV1 antagonist
was also studied in these experiments, capsazepine (300
μM; 4 min aerosol) was given 4 minutes before antigen
challenge.
Statistics
Data from HEK293OFF cells studies are presented as the
percentage of the maximal response for each agonist. Cal-
culation of IC50 values were determined using GraphPad
Prism v3.02 (GraphPad Software, Inc.). Data from the
cough studies are expressed as cough number due to
either a capsaicin or a ovalbumin 4 minute exposure. Val-
ues displayed in the figures represent the MEAN ± SEM of
6–12 animals per group. Data were evaluated using a non
parametric Kruskal Wallis in conjunction with a Mann
Whitney U. Statistical significance was set at p < 0.05.
Drugs
Capsaicin, capsazepine, and phorbol 12-myristate 13-ace-
tate (PMA) were purchased from Sigma (St. Louis, MO,
USA). N-(4-Tertiarybutylphenyl)-4(3-cholorphyridin-2-
yl)tetrahydropyrazine1(2H)-carbox-amide (BCTC) was
synthesized based on to published reports and was tested
in all experiments as the free base (molecular weight
372.89) [24]. For molecular and in vtiro studies drugs
were dissolved in dimethylsulfoxide (DMSO) and stored
at -20.0 °C. The final concentration of DMSO was less
than 0.1% (v/v) in these studies. For in vivo studies, cap-
saicin and capsazepine were dissolved in 10% ethanol
and physiological saline (0.9%), respectively. BCTC was
dissolved in warm (58°C) 45% (2-hydroxypropyl-) β-
cyclodextrin.Cough 2006, 2:10 http://www.coughjournal.com/content/2/1/10
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Results
Intracellular Ca2+ concentration measurements in 
HEK293OFF cells
The TRPV1 antagonist BCTC was tested for its ability to
inhibit various modalities of guinea pig TRPV1 activation.
BCTC dose-dependently inhibited capsaicin-induced acti-
vation and PMA-mediated activation of guinea pig TRPV1
with IC50 values of 12.2 ± 5.2 nM, and 0.85 ± 0.10 nM,
respectively (see Figure 1A). The addition of 50 nM PMA
to gpTRPV1 expressing cells which were pre-incubated
with 1 μM Ro 31–8220, a PKC inhibitor, elicited no
response (data not shown). Additionally, capsazepine was
able to block both modes of TRPV1 activation with poten-
cies relative to previously described results [27]. The inclu-
sion of 100 nM BCTC completely blocked the ability of
gpTRPV1 to respond to decreases in pH (see Figure 1B).
Nodose ganglia
Previously we have shown that capsaicin increases intrac-
ellular Ca2+ in guinea pig nodose ganglia cell, in a concen-
tration-dependent manner [28]. In the present study we
evaluate the activity of BCTC against the increase in
nodose intracellular Ca2+ elicited by 0.1 μM capsaicin. The
change in the 334/380 fluorescence ratios due to capsai-
cin (0.1 μM) was 2.08 ± 0.26. BCTC (1 × 10-9 – 1 × 10-7M)
significantly attenuated capsaicin-induced intracellular
Ca2+ responses in nodose ganglia cells (see Figure 2).
Cough studies
In non-sensitized naive animals, aerosolized exposure to
capsaicin (10–300 μM) increased guinea pig cough fre-
quency (see Figure 3). In follow-up studies we used the
300  μM concentration of capsaicin as the provocation
dose to examine the cough suppressant activity of BCTC.
Capsaicin (300 μM) produced 15.6 ± 2.1 coughs over a 4
minute exposure time (see Figure 4). Figure 4 shows that
30 minutes after i.p. administration BCTC (0.01–3.0 mg/
kg, i.p.) dose dependently attenuated the increase in
cough frequency provoked by capsaicin (300 μM). We
found that the optimum experimental protocol for the
BCTC cough studies was to give the drug i.p. 30 minutes
before capsaicin, because by 60 minutes the cough sup-
pressant activity of BCTC was significantly diminished
(see Figure 4). Using the experimental design established
in the capsaicin studies, BCTC (3 mg/kg, i.p.) was admin-
istered in sensitized guinea pigs 30 minutes before cough
was provoked by ovalbumin. BCTC inhibited allergic
cough by 60% (see Figure 5). Doses of BCTC greater than
3 mg/kg could not be tested because of solubility limita-
tions of the drug. To confirm the antitussive actions of
BCTC against antigen-induced cough, a structurally differ-
ent TRPV1 antagonist was also studied. Similar to BCTC,
aerosolized capsazepine (300 μM) blocked cough (-81%)
elicited by ovalbumin (See Figure 5).
Discussion
Recently, van den Worm et al., (2005) demonstrated that
a TRPV1 receptor antagonist inhibits isolated allergen-
Inhibition of TRPV1 polymodal activation by BCTC in HEK293OFF cells Figure 1
Inhibition of TRPV1 polymodal activation by BCTC in HEK293OFF cells. Panel A shows that BCTC antagonizes capsaicin (10 
nM) and PMA-mediated (50 nM) activation of gpTRPV1. Panel B shows that inclusion of 100 nM BCTC completely inhibits 
gpTRPV1 respond to decreases in pH. Data are presented as percent maximal response in the absence of inhibitor (A). Data 
shown are representative of at least three separate experiments.
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induced tracheal contractions [29]. The objective of the
present studies was to examine the role of TRPV1 recep-
tors in an allergic "disease" cough model. To this end, we
utilized the recently described TRPV1 antagonist, BCTC,
as a pharmacological tool in our experiments. BCTC has
been shown to inhibit rat TRPV1 channels. However, its
effect on guinea pig TRPV1 has not been tested previously.
Prior to advancing BCTC into in guinea pig in vitro and in
vivo experiments, we first characterized the activity of this
drug on guinea pig TRPV1 in HEK293OFF cells that heter-
ologously expressed cloned guinea pig TRPV1 receptor.
We found the BCTC effectively antagonized the prototyp-
ical activity of the vanilloid receptor agonist, capsaicin.
Additionally, BCTC abolished proton-mediated and
antagonized PKC-phosphorylation-induced activation of
TRPV1. The potency of BCTC against PMA-induced activa-
tion was significantly more potent than against capsaicin-
driven activation. The mechanism behind this difference
is unclear, however, we have observed that BCTC is more
potent in antagonizing PMA-induced activation in other
TRPV1 orthologues including human, mouse and rat [26].
Stimulation of a PKC phosphorylation pathway could
link TRPV1 mediated pulmonary responses with the
upstream activation of cell surface receptors such as the
purinergic receptor P2Y1, bradykinin BK2 receptor, PAR2,
histamine H1 receptor, or the nerve growth factor (NGF)
receptor TrkA [6-8,30]. Indeed, recent results demonstrate
that PAR2-mediated sensitization of TRPV1 enhances the
overall cough reflex and, by utilizing specific inhibitors,
this exaggerated response appears to be mediated via
PAR2 -induced PKC and/or PKA activity. Therefore, our
results suggest that BCTC may not only effectively antago-
nize the direct activation of TRPV1 receptors via small
molecule but may also block the actions of inflammatory
Effect of BCTC on capsaicin-induced cough in non-sensitized  guinea pigs Figure 4
Effect of BCTC on capsaicin-induced cough in non-sensitized 
guinea pigs. Figure demonstrates the cough suppressant 
activity of BCTC (0.01 – 3.0 mg/kg, i.p.) administered at 30 
and 60 minutes before capsaicin (300 μM) provocation. Each 
bar represents the Mean ± SEM of the number of coughs 
produced by a 4 min exposure to capsaicin. Control animals 
were guinea pigs that received oral vehicle instead of BCTC 
and were exposed to capsaicin provocation. (*p < 0.05 com-
pared to control animals using a Kruskal-Wallis in conjunc-
tion with a Mann-Whitney-U; n = 8–9 per treatment group).
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Intracellular Ca2+ in response to capsaicin (0.1 μM) was 
measured in isolated guinea pig nodose ganglia neurons and 
expressed as 334/380 ratio change. When cells were prein-
cubated with BCTC, capsaicin-induced Ca2+ response was 
inhibited in a concentration dependent manner. * p < 0.05 
compared with control (n = 5–12).
C o n t r o l - 9- 8- 7
0.0
0.5
1.0
1.5
2.0
2.5
BCTC Concentration (log M)
3
3
4
/
3
8
0
 
R
a
t
i
o
 
C
h
a
n
g
e
i
n
 
R
e
s
p
o
n
s
e
 
t
o
C
a
p
s
a
i
c
i
n
*
* *
Tussigenic effects of capsaicin in non-sensitized conscious  guinea pigs Figure 3
Tussigenic effects of capsaicin in non-sensitized conscious 
guinea pigs. Figures shows that aerosolized capsaicin (10 – 
300 μM, 4 min exposure; n = 6–8 per treatment group) pro-
duces a dose-dependent increase in cough frequency in 
guinea pigs. The tussigenic response to a saline (which pro-
duced no coughing; n = 5) is not shown in the figure.
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mediators (trypsin, bradykinin, histamine, e.g.) that may
indirectly contribute to TRPV1 activation/sensitization, by
stimulating PKC activity. Furthermore, our experiments
also demonstrate that the antagonist activity of BCTC is
observed at the level of the native TRPV1 receptor in
guinea pig nodose ganglia. The present BCTC data are
consistent with previous finding showing that capsaicin-
induced Ca2+ responses in isolated guinea-pig nodose
ganglia cells are blocked by the TRPV1 antagonist, cap-
sazepine [17]. Nodose ganglia cells relay sensory impulses
into the CNS from a variety of visceral organs, including
the pulmonary system. Moreover, nodose ganglia (and
jugular ganglia) contain the cell bodies of airway afferent
sensory nerves that are involved in the cough reflex. Thus,
our in vitro studies indicate, at least in part, a peripheral
pharmacological action for BCTC on C-fibers nerves
which are known to express TRPV1 receptors. Activity of
BCTC on respiratory associated C-fibers likely contributes
to the antitussive action of this drug observed in our
cough models.
Chemical irritants such as capsaicin and citric acid are
often used to elicit cough in experimental models. Both
capsaicin and citric acid directly activate TRPV1. There-
fore, it is not surprising that BCTC inhibited cough pro-
duced by aerosolized capsaicin exposure to the airways.
We sort to examine the antitussive effects of BCTC in an
ovalbumin sensitized guinea pig model. We found that
BCTC and capsazepine suppressed antigen-evoked cough
in the ovalbumin sensitized guinea pigs. Previous work by
Bolser et al., (1995) demonstrated that allergic guinea pig
could be used to characterize the cough suppressant activ-
ity of different pharmacological classes of antitussive
drugs, including opioids, such as codeine [20]. Two defin-
ing features of the allergic guinea pig model are respira-
tory inflammation (mainly eosinophilia) and a
hyperresponsiveness to pulmonary constricting agents
such as histamine and methacholine [31]. It is becoming
increasingly evident that pulmonary inflammation alters
the excitability of afferent airway nerves that are impor-
tant in the initiation of cough [18,32]. However, the
mechanism(s) by which the excitability of sensory nerves
is increased after inflammation is not completely estab-
lished. Nevertheless, several studies have demonstrated
that allergic inflammation significantly enhances the
expression of tachykinins (SP and NKA) and tachykinin
receptors (NK2  subtype) in vagal nodose ganglia
[18,33,34]. It is also possible that chronic inflammation
may enhance the functionality of afferent cough nerves at
the level of the TRPV1 receptor. The sensitivity of capsai-
cin-induced cough responses following upper respiratory
tract infection and in airway inflammatory diseases such
as asthma and COPD, is increased relative to control
responses [22,23]. Our findings in conjunction with
above mentioned studies strongly support the position
that TRPV1 is an attractive pharmacological target for the
development of new antitussive drugs. Moreover, TRPV1
may have an increasing relevance as a target in respiratory
diseases as inflammation becomes progressively chronic.
An important characteristic of the allergic guinea pig is
that pulmonary exposure of antigen can produce an acute
bronchoconstriction. The extent to which bronchocon-
striction contributes to cough responses in the present
model is not clear. It should be pointed out that bron-
choconstriction and cough are not necessarily linked
occurrences and may be mediated by different mecha-
nisms [35]. In support of this hypothesis, we have found
that when a prominent mast cell mediator, histamine
(0.01%), is aerosolized to conscious naive guinea pigs it
produces a 700% increase in a, Penh (a surrogate marker
of bronchoconstriction; data not shown). On the other
hand, this same concentration of histamine does not elicit
cough. Nonetheless, studies to determine the extent to
which BCTC and capsazepine attenuates antigen-evoked
bronchoconstriction is beyond the scope of this report.
This report focuses solely on TRPV1 blockade and antigen
mediated tussigenic responses.
In summary, the data from this study show that TRPV1
antagonists inhibit cough elicited by aerosol exposure of
ovalbumin in sensitized guinea pigs. The present study
Effect of BCTC on cough responses elicited by antigen chal- lenge in sensitized guinea pigs Figure 5
Effect of BCTC on cough responses elicited by antigen chal-
lenge in sensitized guinea pigs. BCTC (1 and 3 mg/kg, i.p.) 
blocked the increase in cough produced by antigen ovalbu-
min (0.3%) challenge. Also shown are the activities of a sec-
ond TRPV1 antagonist (given by aerosol 4 min before antigen 
provocation*), capsazepine (300 μM) on allergic cough. Each 
bar represents the Mean ± SEM of the number of coughs 
produced by a 4 min exposure to capsaicin. (*p < 0.05 com-
pared to controls (sensitized and administered vehicle) ani-
mals using a Kruskal-Wallis in conjunction with a Mann-
Whitney-U; n = 9–16).
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suggests that TRPV1 may play an important role in inflam-
matory cough. Specifically, in cough associated with pul-
monary inflammation, such as found in some asthmatic
patients.
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